MTOS 2022 Presentations

Please find the Presentations from the MTOS 2022 Virtual Symposium available below for viewing and downloading (in PDF format). We again thank our world-renowned faculty for taking part in this year’s exciting scientific symposium.

Nuclear Oncology Workshop – Presentations
Advances in Radioactive Iodine Theranostics

• Nuclear Medicine in the Evolving Paradigm of RAI Theranostics
  Changing Concepts in RAI Theranostics
  Interdisciplinary Communication and Collaboration
  Presented by Dr. Frederick Grant, M.D.

• Physiologic and Molecular Basis of RAI Theranostics
  Tumor Biology and RAI Physiology: Iodine Metabolism and RAI Kinetics.
  MAPK and TDS
  Theranostic and Therapeutic Power and Performance
  Presented by Dr. Seza Gulec, M.D., F.A.C.S., F.A.C.N.M.

• Regulation of Differentiation State in Thyroid Cancer
  ERK Upstream and Downstream Substrates
  ERK Action on Thyroid Differentiation
  Thyroid Differentiation Score
  Presented by Dr. James Fagin, M.D.

• Molecular Diagnostics and Theranostics
  Mutational Landscape of Malignant Thyroid Nodules
  Gene Expression Alterations
  Potential Impact on RAI Theranostics
  Presented by Dr. Yuri Nikiforov, M.D., Ph.D.

• Thyroglobulin: Biology, Physiology, and Clinical Meaning
  Thyroglobulin Physiology
  Pitfalls and Caveats in Clinical Testing
  Diagnostic and Prognostic Value of Thyroglobulin
  Presented by Dr. Luca Giovanella, M.D.

• Radiobiology of I-131
  Safety of RAI Treatment
  Safe Cure with Curie: Facts and Fiction
  Deterministic and Stochastic effect
  Presented by Dr. Markus Luster, M.D.

• Appropriate Use of RAI in 2022
  Principles of RAI Ablation and Therapy
  The RAI Tradition and Evolving Theranostic Paradigm
  Impact of Advances in Molecular Medicine in Thyroid Cancer Management.
  Presented by Dr. Bennett Greenspan, M.D., F.A.C.N.P.

• Refractory Thyroid Cancer
  Definitions and Classifications:
  RAI Refractory Disease, RAI Resistant Disease, RAI Indifferent Cancer
  Presented by Dr. Douglas Van Nostrand, M.D., F.A.C.P., F.A.C.N.P.

• PET/CT Imaging in Thyroid Cancer
  FDG-PET/CT
  I-124 PET/CT
  F-18 TFB PET/CT
  Presented by Dr. Steven Larson, M.D., F.A.C.N.P.

• Post-Thyroidectomy RAI Imaging and Ablation
  Remnant Anatomy for Surgeons and Nuclear Medicine Physicians
  The Theranostic Performance of Post-Thyroidectomy Imaging
  Presented by Dr. Seza Gulec, M.D., F.A.C.S., F.A.C.N.M.

• RAI Dosimetry
  Rationale and Outcomes of Dosimetry
  Clinical Feasible Techniques
  Presented by Dr. Steven Larson, M.D., F.A.C.N.P.

Plenary Session – Presentations
Frontiers in Thyroid Oncology

• Molecular Pathology of Differentiated Thyroid Cancer
  Presented by Dr. Yuri Nikiforov, M.D., Ph.D.

• Mutational and Molecular Landscape of PDTC and UDTC
  Presented by Dr. Maria Cabanillas, M.D.

• Perioperative Risk Stratification in Thyroid Cancer
  Presented by Dr. R. Michael Tuttle, M.D.

• The role of Molecular Testing in Perioperative Risk Stratification
  Presented by Yuri Nikiforov, M.D., Ph.D.

• Science of Thyroidectomy in the Molecular Theranostics Paradigm
  Presented by Dr. Seza Gulec, M.D., F.A.C.S., F.A.C.N.M.

• Science of RAI in the Molecular Theranostics Paradigm
  Presented by Dr. Douglas Van Nostrand, M.D., F.A.C.P., F.A.C.N.P.

• Targeted Therapies for Aggressive Thyroid Cancer
  Presented by Dr. Maria Cabanillas, M.D.

• Redifferentiation Trials
  Presented by Dr. James Fagin, M.D.

• Active Surveillance for Malignant Nodules
  Presented by Dr. R. Michael Tuttle, M.D.

• Ablative Approaches to Thyroid Nodules
  Presented by Dr. Erivelto Volpi, M.D.

• Clinical Molecular Testing Platforms
  Presented by Dr. Atil Kargi, M.D.